Zacks Investment Research upgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a sell rating to a hold rating in a research report report published on Wednesday, September 12th.
According to Zacks, “CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. “
CRSP has been the subject of a number of other research reports. BidaskClub downgraded Crispr Therapeutics from a strong-buy rating to a buy rating in a research note on Tuesday, June 5th. Chardan Capital reissued a buy rating and set a $72.50 target price on shares of Crispr Therapeutics in a research report on Wednesday, August 8th. Citigroup dropped their target price on shares of Crispr Therapeutics from $51.00 to $50.00 and set a neutral rating on the stock in a research report on Friday, August 24th. Finally, ValuEngine raised shares of Crispr Therapeutics from a hold rating to a buy rating in a research report on Saturday, June 2nd. Two analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company’s stock. Crispr Therapeutics presently has a consensus rating of Hold and an average price target of $65.78.
Shares of CRSP traded up $1.00 during trading hours on Wednesday, hitting $38.56. The stock had a trading volume of 886,402 shares, compared to its average volume of 1,230,400. The company has a market cap of $2.09 billion, a PE ratio of -22.55 and a beta of 3.70. Crispr Therapeutics has a 1-year low of $16.51 and a 1-year high of $73.90.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, August 8th. The company reported ($0.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.19). The firm had revenue of $1.09 million during the quarter, compared to analyst estimates of $1.47 million. Crispr Therapeutics had a negative net margin of 245.57% and a negative return on equity of 39.58%. Equities research analysts predict that Crispr Therapeutics will post -2.92 earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. purchased a new position in Crispr Therapeutics in the 2nd quarter valued at approximately $116,000. Signaturefd LLC grew its position in shares of Crispr Therapeutics by 123.8% during the 2nd quarter. Signaturefd LLC now owns 2,350 shares of the company’s stock valued at $138,000 after purchasing an additional 1,300 shares in the last quarter. First Mercantile Trust Co. purchased a new position in shares of Crispr Therapeutics during the 2nd quarter valued at $141,000. SeaCrest Wealth Management LLC grew its position in shares of Crispr Therapeutics by 202.9% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 2,726 shares of the company’s stock valued at $160,000 after purchasing an additional 1,826 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Crispr Therapeutics by 66.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,827 shares of the company’s stock valued at $166,000 after purchasing an additional 1,127 shares in the last quarter. Institutional investors and hedge funds own 39.13% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Featured Article: Why is the conference call important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.